Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5020- UA,    Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway
- in-vitro, Ovarian, NA
tumCV↓, selectivity↑, BAX↑, Bcl-2↓, Apoptosis↑, ROS↑, TumCCA↑, Akt↓, PI3K↓,
5021- UA,    Anticancer effect of ursolic acid via mitochondria-dependent pathways
- Review, Var, NA
Inflam↓, TNF-α↓, IL6↓, IL17↓, NF-kB↓, COX2↓, *AntiDiabetic↑, *hepatoP↑, ALAT↓, AST↓, TumCP↓, Apoptosis↑, TumCCA↑, TumAuto↑, tumCV↓, TumCMig↓, Glycolysis↓, ATP↓, lactateProd↓, HK2↓, PKA↓, COX2↓, mtDam↑, Casp3↑, Casp8↑, Casp9↑, Akt↓, ROS↑, MMP↓, P53↑,
5022- UA,    Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks
- Review, Var, NA
TumCP↓, Apoptosis↑, angioG↑, TumMeta↓, BioAv↓, Hif1a↓, Glycolysis↓, mitResp↓, Akt↓, MAPK↓, ERK↓, mTOR↓, P53↑, P21↑, E2Fs↑, STAT3↓, MMP↓, NLRP3↓, iNOS↓, CHK1↓, Chk2↓, BRCA1↓, E-cadherin↑, N-cadherin↓, Casp↑, p62↓, LC3II↑, Vim↓, ROS↑, CSCs↓, DNAdam↑, GutMicro↑, VEGF↓,
5023- UA,  CA,  RosA,    Therapeutic Effect of Rosemary and Its Active Constituent on Nervous System Disorders
- Review, Park, NA - Review, AD, NA
*memory↑, *cognitive↑, *ROS↓,
3790- UA,    Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools
*Inflam↓, *antiOx↑, AntiCan↑, *neuroP↑, *hepatoP↑, *cardioP↑, *MMP↑, *ROS↓, *PGC-1α↑, *BDNF↑, *cognitive↑, Bcl-2↓, Cyt‑c↑, DR5↑, Casp9↑, Casp8↑, Casp3↑, TumCCA↑, *BioAv↓, *Dose↝, *Half-Life↓, *Half-Life↓,
3789- UA,  Ex,    Combined Ursolic Acid and Resistance/Endurance Training Improve Type 3 Diabetes Biomarkers-Related Memory Deficits in Hippocampus of Aged Male Wistar Rats
- in-vivo, AD, NA
*BDNF↑,
3788- UA,  RosA,    Ursolic acid and rosmarinic acid ameliorate alterations in hippocampal neurogenesis and social memory induced by amyloid beta in mouse model of Alzheimer’s disease
- in-vivo, AD, NA
*neuroP↑, *Aβ↓, *p‑tau↓, *memory↑, *Inflam↓, *ROS↓,
1139- UA,    Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells
- in-vitro, Lung, A549
TumMeta↓, AEG1↓, E-cadherin↑, N-cadherin↓, Vim↓, EMT↓,
1058- UA,    Ursolic acid, an antagonist for transforming growth factor (TGF)-beta1
- in-vivo, NA, NA
TGF-β↓,
1020- UA,    Root Bark of Morus alba L. and Its Bioactive Ingredient, Ursolic Acid, Suppress the Proliferation of Multiple Myeloma Cells by Inhibiting Wnt/β-Catenin Pathway
- in-vitro, Melanoma, RPMI-8226
β-catenin/ZEB1↓, TCF↓, cMyc↓, cycD1/CCND1↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, Casp7↑,
119- UA,  CUR,  RES,    Combinatorial treatment with natural compounds in prostate cancer inhibits prostate tumor growth and leads to key modulations of cancer cell metabolism
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
ROS⇅, p‑STAT3↓, Src↓, AMPK↑, GlutMet↑, TCA↑, glut↓,
942- UA,    Ursolic Acid Inhibits Breast Cancer Metastasis by Suppressing Glycolytic Metabolism via Activating SP1/Caveolin-1 Signaling
- vitro+vivo, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Cav1↑, Glycolysis↓, cMyc↓, LDHA↓, Nrf1↓, PGC-1α↓, Sp1/3/4↑, TumCG↓,
2350- UA,    Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
Akt↓, Glycolysis↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, AMPK↑, TumAuto↑, Apoptosis↑, ERK↓, MMP↓, NO↑, ROS↑, DNAdam↑,
2411- UA,    Ursolic acid in health and disease
- Review, Var, NA
Inflam↓, antiOx↑, NF-kB↓, Bcl-xL↓, Bcl-2↓, cycD1/CCND1↓, Ki-67↓, CD31↓, STAT3↓, EGFR↓, P53↑, P21↓, HK2↓, PKM2↓, ATP↓, lactateProd↓, p‑ERK↓, MMP↓, NO↑, ATM↑, Casp3↑, AMPK↑, JNK↑, FAO↑, FASN↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *GSTs↑, neuroP↑,
1310- UA,    Ursolic acid triggers apoptosis and Bcl-2 downregulation in MCF-7 breast cancer cells
- in-vitro, BC, MCF-7
GR↝, AP-1↝, cl‑PARP↑, Bcl-2↓,
4869- Uro,    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,
4859- Uro,  Rad,    Urolithin A Enhances Tight Junction Protein Expression in Endothelial Cells Cultured In Vitro via Pink1-Parkin-Mediated Mitophagy in Irradiated Astrocytes
- in-vitro, Nor, NA
*ROS↓, *VEGF↓,
4868- Uro,    Urolithin A improves Alzheimer’s disease cognition and restores mitophagy and lysosomal functions
- in-vivo, AD, NA
*memory↑, *Aβ↓, *tau↓, *MitoP↑, *lysosome↑, *CTSZ↝,
4867- Uro,    Urolithin A exhibits a neuroprotective effect against Alzheimer’s disease by inhibiting DYRK1A activity
- in-vivo, AD, NA - in-vitro, AD, HEK293
*neuroP↑, *DYRK1A↓, *memory↑, *p‑tau↓, *Inflam↓,
4865- Uro,    Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis
- in-vitro, Diabetic, NA - in-vitro, AD, NA
*antiOx↑, *neuroP↑, *Ca+2↓, *Aβ↓, *BACE↓, *p‑tau↓, *cognitive↑,
4864- Uro,    Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer's Disease
- Review, AD, NA
*neuroP↑, *Half-Life↝, *BBB↑, *toxicity↓, *Inflam↓, *Strength↑, *BACE↓, *Aβ↓, *MitoP↑, *SIRT1↑, *SIRT3↑, *AMPK↑, *PGC-1α↑, *mTOR↓, *PARK2↑, *Beclin-1↑, *ROS↓, *GutMicro↑, *Risk↓,
4863- Uro,    Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease
- in-vivo, AD, NA
*memory↑, *Aβ↓, *OS↑, *cognitive↑,
4862- Uro,    Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease
- in-vivo, AD, NA - in-vitro, Nor, PC12
*cognitive↑, *p‑PI3K↓, *p‑Akt↓, *AMPK↑, *VDAC1↓, *neuroP↑, *PARK2↑, *PTEN↑, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p62↓, *Aβ↓, *Apoptosis↓,
4861- Uro,    Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions
- in-vivo, AD, NA
*memory↑, *Aβ↓, *toxicity↓, *BBB↑, *p‑tau↓, *eff↓, *IL1α↓, *MCP1↓, *MIP‑1α↓, *TNF-α↓, *IL2↓, *SIRT1↓, *DNAdam↓, *Dose↝, *Strength↑, *motorD↑, *CTSZ↓,
4860- Uro,    Urolithins–gut Microbial Metabolites with Potential Health Benefits
- Review, Nor, NA - Review, AD, NA - Review, Park, NA
*ROS↓, *Inflam↓, TumCG↓, *neuroP↑, *cardioP↑, *LDL↓, *BioAv↝, *BioAv↓, *BioAv↑, *SIRT1↑, *mTOR↑, *BDNF↑, *cognitive↑,
4857- Uro,    Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study
- in-vitro, ESCC, KYSE-30
tumCV↓, selectivity↑, TumCCA↑, ROS↑, Bcl-2↓, BAX↑, P21↑, MMP2↓, MMP9↓,
4870- Uro,    Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice
- in-vivo, AD, NA
*cognitive↑, *Apoptosis↓, *neuroP↑, *Aβ↓, *AMPK↑, *NF-kB↓, *MAPK↓, *BACE↑, *neuroG↑, *Inflam↓, *memory↑,
4871- Uro,  DHA,  LT,    A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease
- in-vitro, AD, NA
*ATP↑, *Apoptosis↓,
4872- Uro,    Urolithin A exhibits a neuroprotective effect against Alzheimer's disease by inhibiting DYRK1A activity
- in-vitro, AD, HEK293
*DYRK1A↓, *antiOx↑, *Inflam↓, *neuroP↑, *memory↑, *p‑tau↓, *Aβ↓, *neuroP↑,
4873- Uro,    Urolithin A Inhibits Anterior Basolateral Amygdala to Ventral Hippocampal CA1 Circuit to Ameliorate Amyloid-β-Impaired Social Ability
- in-vivo, AD, NA
*Aβ↓, *cognitive↑,
4874- Uro,  EGCG,    A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease
- in-vivo, AD, NA
*motorD↑, *memory↑, *MitoP↑, *Aβ↓, *mitResp↑, *Nrf1↑, *PINK1↑, *PARK2↑, *ATG5↑, *Bcl-2↑, *H2O2↓, *ROS↓, *lipid-P↓, *mt-ATP↑,
4875- Uro,    Impact of the Natural Compound Urolithin A on Health, Disease, and Aging
- Review, AD, NA - Review, Stroke, NA - Review, ostP, NA - Review, IBD, NA
*MitoP↓, *Strength↑, *PINK1↑, *PARK2↑, *Inflam↓, *COX2↓, *IL1β↓, *IL6↓, *TNF-α↓, *OS↑, *cardioP↑, *memory↑, *neuroG↑, *neuroP↑, *Cartilage↑, *Inflam↓, *RenoP↑, *eff↑, *Dose↝, *Half-Life↑, *NRF2↑, *GutMicro↑,
4876- Uro,    Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management
- Review, Park, NA - Review, AD, NA
*Inflam↓, *antiOx↓, *neuroP↑, *p‑tau↓, *Aβ↓, *eff↑, *BioAv↓, *BioAv↑, *GSH↑, *SOD↑, *lipid-P↓, *Catalase↑, *GSR↑, *GPx↑, *ROS↓, *NRF2↑, *GutMicro↑, *Risk↓, *BBB↓, *NLRP3↓, *MAOA↓,
4877- Uro,    Urolithin-A Derivative UAS03 Improves Cognitive Deficits and Memory by Activating Nrf2 Pathways to Alleviate Oxidative Stress and Neuroinflammation
- in-vivo, AD, NA
*cognitive↑, *memory↑, *neuroP↑, *NRF2↑, *ROS↓, *Inflam↓, *IL1β↓, *TNF-α↓, *COX2↓,
4878- Uro,    Activation of the Gut–Brain Interaction by Urolithin A and Its Molecular Basis
- Review, AD, NA
*memory↑, *SIRT1↑, *cognitive↑, *BDNF↑, *Apoptosis↓, *neuroG↑,
4879- Uro,    Neuroprotective Effect of Urolithin A against Cerebellum Changes in Streptozotocin-Induced Alzheimer’s Disease Rat Model
- in-vitro, AD, NA
*neuroP↑,
4880- Uro,    Urolithins: A Prospective Alternative against Brain Aging
- Review, AD, NA
*cognitive↑, *memory↑, *antiOx↑, *BBB↑, *ROS↓, *lipid-P↓, *Catalase↑, *SOD↑, *GSR↑, *GPx↑, *CREB↑, *BDNF↑, *neuroP↑, *Inflam↓, *MitoP↑, *Aβ↓, *tau↓, *NLRP3↓, *SIRT1↑, *SIRT3↑,
4884- Uro,    A review of pomegranate supplementation: A promising remedial avenue for Alzheimer's disease
- Review, AD, NA
*antiOx↑, *neuroG↑, *Inflam↓, *cognitive↑,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4833- Uro,    Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine
- Review, Var, NA - Review, AD, NA - Review, IBD, NA
BioAv↝, TumAuto↝, TumCG↓, TumMeta↓, ChemoSen↑, Imm↑, RadioS↑, BioAv↑, other↝, eff↓, *antiOx↓, *Inflam↓, AntiCan↓, AntiAge↑, chemoP↑, *neuroP↑, *ROS↓, *cognitive↑, *lipid-P↓, *cardioP↑, *TNF-α↓, *IL6↓, GutMicro↑, TumCCA↑, Apoptosis↑, angioG↓, NF-kB↓, PI3K↓, Akt↓, Casp↑, survivin↓, TumCP↓, cycD1/CCND1↓, cMyc↑, BAX↑, Bcl-2↓, COX2↓, P53↑, p38↑, *ROS↓, *SOD↑, *GPx↑, SIRT1↑, FOXO1↑, eff↑, ChemoSen↑,
4834- Uro,    Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer
- Human, Pca, NA
eff↑, NK cell↑,
4835- Uro,    Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway
- in-vitro, SCC, NA
TumCD↑, ER Stress↑, Akt↓, mtDam↓, p‑mTOR↓, *BioAv↝, ROS↑, TumCCA↑, Apoptosis↑, ERK↓,
4836- Uro,    Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation
- in-vitro, Var, NA
FOXO1↑, TumCG↓, PD-1↓, TIM-3↓,
4837- Uro,    Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in Cancer Prevention, a Review
- Review, Var, NA
AntiCan↑, TumCCA↑, Apoptosis↑, TumAuto↑, *BioAv↝, *BioAv↑, RAS↓, ERK↓, AR↓, TumCP↓, PI3K↓, Akt↓, NF-kB↓, COX2↓, IL6↓, IL1β↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, P53↑, Casp3↑, PARP↑, ROS↓, toxicity↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4839- Uro,    Urolithin A induces prostate cancer cell death in p53-dependent and in p53-independent manner
- in-vitro, Pca, 22Rv1 - in-vitro, Pca, LNCaP
tumCV↓, Apoptosis↓, P53↑, P21↑, PUMA↑, NOXA↑, MDM2↓, XIAP↓,
4840- Uro,    Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer
- vitro+vivo, BC, NA
MMP↓, TumCP↓, Apoptosis↑, tumCV↓, ER-α36↝, *toxicity↓,
4841- Uro,    Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells
- in-vitro, CRC, HT29 - in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
TumCP↓, TumCCA↑, Apoptosis↑, P53↑, P21↑, Bcl-2↓, Cyt‑c↑, Casp↑, ROS↑, *ROS↓,
4842- Uro,    Urolithin A inhibits breast cancer progression via activating TFEB-mediated mitophagy in tumor macrophages
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vitro, BC, MCF-7 - in-vitro, BC, 4T1
Inflam↓, IL6↓, TNF-α↓, eff↑, STAT3↓, TumCP↓, TumCMig↓,
4843- Uro,    The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide
- in-vitro, Pca, LNCaP
TumCP↓, eff↑, ChemoSen↝,

Showing Research Papers: 5601 to 5650 of 5938
Prev Page 113 of 119 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5938

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Nrf1↓, 1,   ROS↓, 1,   ROS↑, 8,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 3,   mitResp↓, 1,   MMP↓, 6,   mtDam↓, 1,   mtDam↑, 1,   PGC-1α↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 3,   Cav1↑, 1,   cMyc↓, 3,   cMyc↑, 1,   FAO↑, 1,   FASN↓, 1,   glut↓, 1,   GlutMet↑, 1,   Glycolysis↓, 4,   HK2↓, 3,   lactateProd↓, 3,   LDHA↓, 1,   PKM2↓, 2,   SIRT1↑, 1,   TCA↑, 1,  

Cell Death ⓘ

Akt↓, 7,   p‑Akt↓, 1,   Apoptosis↓, 1,   Apoptosis↑, 11,   BAX↑, 4,   Bcl-2↓, 7,   Bcl-xL↓, 1,   Casp↑, 3,   Casp3↑, 4,   cl‑Casp3↑, 2,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 2,   Chk2↓, 1,   Cyt‑c↑, 2,   DR5↑, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↓, 1,   MDM2↓, 1,   MDM2↑, 1,   NOXA↑, 1,   p38↑, 1,   PUMA↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↑, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,   tumCV↓, 5,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p62↓, 1,   TumAuto↑, 3,   TumAuto↝, 1,  

DNA Damage & Repair ⓘ

ATM↑, 1,   BRCA1↓, 1,   CHK1↓, 1,   DNAdam↑, 2,   P53↑, 7,   p53 Wildtype↑, 1,   PARP↑, 2,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 3,   E2Fs↑, 1,   P21↓, 1,   P21↑, 4,   TumCCA↑, 9,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 1,   EMT↓, 3,   ERK↓, 4,   p‑ERK↓, 1,   FOXO1↑, 2,   mTOR↓, 2,   p‑mTOR↓, 1,   PI3K↓, 3,   RAS↓, 1,   Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TCF↓, 1,   TumCG↓, 4,   Wnt↓, 1,  

Migration ⓘ

AEG1↓, 1,   AP-1↝, 1,   CD31↓, 1,   E-cadherin↑, 4,   ER-α36↝, 1,   Ki-67↓, 1,   MMP2↓, 2,   MMP9↓, 2,   N-cadherin↓, 4,   PKA↓, 1,   Snail↓, 2,   TGF-β↓, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumCP↓, 10,   TumMeta↓, 3,   Vim↓, 4,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   angioG↑, 1,   EGFR↓, 1,   Hif1a↓, 1,   NO↑, 2,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   IL17↓, 1,   IL1β↓, 2,   IL6↓, 4,   Imm↑, 1,   Inflam↓, 4,   NF-kB↓, 5,   NK cell↑, 1,   PD-1↓, 1,   TNF-α↓, 2,  

Cellular Microenvironment ⓘ

TIM-3↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,   GR↝, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   BioAv↝, 1,   ChemoSen↑, 2,   ChemoSen↝, 1,   eff↓, 2,   eff↑, 4,   RadioS↑, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AR↓, 1,   AST↓, 1,   BRCA1↓, 1,   EGFR↓, 1,   GutMicro↑, 2,   IL6↓, 4,   Ki-67↓, 1,   NOS2↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 1,   AntiCan↓, 1,   AntiCan↑, 2,   chemoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 152

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 2,   antiOx↑, 6,   Catalase↑, 4,   Ferroptosis↓, 1,   GPx↑, 4,   GSH↑, 2,   GSR↑, 2,   GSTs↑, 1,   H2O2↓, 1,   HO-1↑, 1,   lipid-P↓, 5,   Nrf1↑, 1,   NRF2↑, 4,   PARK2↑, 5,   ROS↓, 14,   SIRT3↑, 2,   SOD↑, 5,   VDAC1↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 2,   mt-ATP↑, 1,   mitResp↑, 1,   MMP↑, 2,   PGC-1α↑, 2,   PINK1↑, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 4,   CREB↑, 1,   LDL↓, 1,   SIRT1↓, 1,   SIRT1↑, 4,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↓, 5,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-2↑, 1,   Casp3↑, 1,   Ferroptosis↓, 1,   MAPK↓, 2,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   DYRK1A↓, 2,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   lysosome↑, 1,   MitoP↓, 1,   MitoP↑, 5,   p62↓, 2,   p62↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

mTOR↓, 2,   mTOR↑, 1,   neuroG↑, 4,   PI3K↓, 1,   p‑PI3K↓, 1,   PTEN↑, 1,  

Migration ⓘ

Ca+2↓, 1,   Cartilage↑, 2,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↓, 1,   BBB↑, 4,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CRP↓, 1,   CTSZ↓, 1,   CTSZ↝, 1,   IL1α↓, 1,   IL1β↓, 3,   IL2↓, 1,   IL6↓, 3,   Inflam↓, 15,   MCP1↓, 1,   MIP‑1α↓, 1,   NF-kB↓, 2,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 5,   MAOA↓, 1,   tau↓, 2,   p‑tau↓, 7,  

Protein Aggregation ⓘ

Aβ↓, 14,   BACE↓, 2,   BACE↑, 1,   NLRP3↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 3,   BioAv↝, 3,   Dose↝, 3,   eff↓, 1,   eff↑, 3,   Half-Life↓, 2,   Half-Life↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

CRP↓, 1,   GutMicro↑, 3,   IL6↓, 3,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 4,   cognitive↑, 13,   hepatoP↑, 2,   memory↑, 13,   motorD↑, 3,   neuroP↑, 17,   OS↑, 2,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 3,   Strength↑, 4,   toxicity↓, 3,  
Total Targets: 105

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page